Cobenfy access in India: the CDSCO Rule 36 named-patient pathway
How families in India who care for an adult living with schizophrenia legally obtain Cobenfy (xanomeline and trospium chloride) from US-source supply, when the first new mechanism in psychiatry in three decades is not yet registered locally.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Cobenfy (xanomeline and trospium chloride) is the first medicine in a new pharmacologic class for adult schizophrenia in more than three decades. The US Food and Drug Administration approved Cobenfy on 26 September 2024. Unlike every previously approved antipsychotic, Cobenfy does not block dopamine D2 receptors. It acts through selective muscarinic receptor activity in the brain, and the trospium component is included to blunt peripheral cholinergic side effects without entering the central nervous system. There is no public record of Cobenfy registration with the Central Drugs Standard Control Organization (CDSCO) as of this review. Patients in India whose treating psychiatrist judges Cobenfy to be the right next step reach the medicine through the CDSCO personal importation framework under Rule 36 of the Drugs and Cosmetics Rules 1945, with Form 12A application and Form 12B permit issued by the Drugs Controller General of India (DCGI), or through the institutional Compassionate Use route at hospitals such as AIIMS New Delhi and the psychiatric units of NIMHANS Bengaluru-affiliated tertiary centres. Reserve Meds coordinates US specialty-pharmacy sourcing, ambient international logistics, and the documentation kit your psychiatrist needs to file.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
How Cobenfy reaches patients in India
Cobenfy (xanomeline plus trospium chloride oral capsule, an M1/M4 muscarinic agonist combined with a peripherally restricted antimuscarinic from Bristol Myers Squibb, FDA-approved 26 September 2024 for adult schizophrenia, label resource at accessdata.fda.gov) is not visible on the Central Drugs Standard Control Organization SUGAM approved-product search at cdscoonline.gov.in as of 2026-06-01. Patients in India access the medicine under the Permission to Import Small Quantities of New Drug for Personal Use, the statutory Form 12-B Permit applied for via Form 12-A under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945 read with the New Drugs and Clinical Trials Rules 2019, pathway page at cdsco.gov.in/Drugs-for-Personal-Use. Applications are filed online through the SUGAM portal at cdscoonline.gov.in/CDSCO/Drugs_Personal. CDSCO public materials describe Form 12-B issuance within one to two working days when documentation is complete. Where a tertiary psychiatric service is the importer-of-record for an admitted named patient, the parallel Import Licence for Personal Use in CT Form-16 under the Second Schedule and Table-1 of the New Drugs and Clinical Trials Rules 2019 applies, rules text at cdsco.gov.in/Acts-and-rules/New-Drugs. The treating psychiatrist must hold current National Medical Commission registration and document the DSM-5 or ICD-11 schizophrenia diagnosis with prior antipsychotic history. The conventional read of the quantity rule supports up to a three-month supply per permit.
Where Cobenfy is dispensed in India
Cobenfy is an oral twice-daily capsule taken at least one hour before or two hours after a meal; the capsule is not crushed or opened. Dispensing routes through tertiary psychiatry programmes with longitudinal antipsychotic management and the laboratory infrastructure for baseline and follow-up liver function tests, blood pressure and heart rate monitoring, and urinary retention assessment. Indian tertiary psychiatric centres include the National Institute of Mental Health and Neuro Sciences Bengaluru (NIMHANS), India's apex psychiatric institute, at nimhans.ac.in; the All India Institute of Medical Sciences New Delhi Department of Psychiatry, at aiims.edu; the Central Institute of Psychiatry Ranchi, a national psychiatric hospital under the Ministry of Health and Family Welfare; the Institute of Human Behaviour and Allied Sciences Delhi (IHBAS); the Department of Psychiatry at the Postgraduate Institute of Medical Education and Research Chandigarh; Christian Medical College Vellore Psychiatry, at clin.cmcvellore.ac.in; and Tata Institute of Social Sciences-affiliated community psychiatry programmes. Among private tertiary nodes, Apollo Hospitals Chennai, Delhi, Hyderabad, Kokilaben Dhirubhai Ambani Hospital Mumbai, Fortis Memorial Research Institute Gurugram, and Medanta The Medicity Gurugram routinely dispense imported psychiatric medications. Direct-to-home delivery outside a licensed dispensing facility is not the model.
What Cobenfy costs in India
Bristol Myers Squibb publishes a US wholesale acquisition cost for Cobenfy of approximately USD 1,887 per 30-day supply, framed by the company as approximately USD 22,500 per year of therapy at the maintenance 125 mg / 30 mg twice-daily dose, sourced from BMS investor materials and Drugs@FDA at accessdata.fda.gov. Titration starts at 50 mg / 20 mg twice daily on days 1 to 2, 100 mg / 20 mg twice daily on days 3 to 7, then 125 mg / 30 mg twice daily from day 8 onward per the FDA label; the geriatric maximum is 100 mg / 20 mg twice daily. No public local-currency benchmark for Cobenfy in INR is observed on the National Pharmaceutical Pricing Authority ceiling-price database at nppaindia.nic.in as of 2026-06-01, consistent with the drug not being CDSCO-registered; do not estimate. Price snapshot: 2026-06-01. Cost layers on top of drug cost include international ambient freight (Cobenfy is stored at controlled room temperature per the FDA label and does not require refrigeration), CDSCO permit and customs handling (nominal relative to drug cost), the dispensing facility's drug-handling fee, and the Reserve Meds concierge fee itemised separately on every firm quote. Goods and Services Tax on most life-saving medicines is 5 percent.
Funding and access barriers for Cobenfy in India
Mental-health financing in India runs through multiple parallel mechanisms. The District Mental Health Programme and the National Mental Health Programme, administered through the Directorate General of Health Services at main.mohfw.gov.in, fund first-line antipsychotics through public-sector channels. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana at INR 5 lakh per family per year hospitalisation cover does not extend to outpatient novel-mechanism antipsychotics outside its listed package set. The Mental Healthcare Act 2017 establishes a rights framework but does not by itself create a payer for unregistered named-patient psychiatric imports. Central Government Health Scheme considers life-saving non-formulary medicines case by case under the Special Director General Expert Committee route, with a stricter review where the drug is not approved by the Drugs Controller General of India. Indian private health insurers including Star Health, Niva Bupa, HDFC ERGO Health, Care Health, ManipalCigna, ICICI Lombard, and Bajaj Allianz assess unregistered named-patient psychiatric imports case by case; mental-health parity rules under IRDAI have improved access to inpatient psychiatric coverage but do not by themselves create coverage for unregistered named-patient imports. The dominant funding pattern is family self-pay, often supported by diaspora remittance. The Cobenfy Cares US patient-support programme operated by Bristol Myers Squibb is US-only and does not extend to international named-patient orders.
Recent regulatory and access news for Cobenfy
The CDSCO Notifications feed at cdsco.gov.in/Notifications has not posted a xanomeline-trospium-specific Indian notification over the last 12 months as of 2026-06-01. Bristol Myers Squibb has continued post-marketing reporting on Cobenfy through 2025 and 2026 disclosures, including phase 3 ARISE adjunctive-therapy trial readouts and EMA filings tracked on the European Medicines Agency human medicines portal at ema.europa.eu. Indian psychiatric academic forums including the Indian Psychiatric Society at indianpsychiatricsociety.org have referenced the novel muscarinic mechanism in continuing medical education content through 2025 and 2026 without an India-specific regulatory action altering Cobenfy availability. India-specific CDSCO registration filings have not appeared on the SUGAM approved-product search at cdscoonline.gov.in as of the snapshot date.
Where Reserve Meds fits in Cobenfy cases
Reserve Meds is a US-based concierge coordinator. We do not replace your psychiatrist, do not replace CDSCO or the DCGI, and do not replace the dispensing hospital pharmacy or the licensed specialty importer. What we do is orchestrate US specialty-pharmacy sourcing of FDA-labeled product through BMS-authorised channels with DSCSA-compliant serialisation, ambient international logistics, and the documentation kit your psychiatrist needs for the Form 12A filing. Operationally Cobenfy is among the most forgiving products we coordinate: small molecule, room-temperature, oral, no REMS, no cold-chain. The work lives in documentation precision and in the family-coordination layer that long-term psychiatric care demands. A single named coordinator carries the case from intake through the titration window and into the maintenance cadence, with the same coordinator on the file across multi-city, multi-country family configurations. No prior Reserve Meds closed case experience exists for Cobenfy in India as of this review; standard NPP coordination applies, with particular attention to family communication around a stigmatised diagnosis.
Next step
If an adult patient in India is living with schizophrenia and the treating psychiatrist is now considering a non-D2-antagonist option after prior-line failure, start your case at the portal. We will respond within 24 to 48 hours with a documentation kit for your psychiatrist and an indicative cost range.
Reserved for you.
This guide is informational, not medical or legal advice. The named-patient framework requires a licensed Indian physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.